Home

Marksans Pharma Ltd EPS

Image

Marksans Pharma Ltd

NSE: MARKSANS

EPS

₹ 8.13

Last updated on: Feb 21, 2025

Key Highlights

  • The Earning per Share of Marksans Pharma Ltd is ₹ 8.13 as of 21 Feb 25 .
  • The earning per share of Marksans Pharma Ltd changed from ₹ 1.52 to ₹ 2.31 over 7 quarters. This represents a CAGR of 27.02% .

Historical Earning per Share of Marksans Pharma Ltd

No data available

* All values are in

Company Fundamentals for Marksans Pharma Ltd

Market Cap

10,246 Cr

EPS

8.1

P/E Ratio (TTM)

27.8

P/B Ratio (TTM)

4.5

Day’s High

236.4

Day’s Low

224.5

DTE

0.1

ROE

15.2

52 Week High

358.5

52 Week Low

126.05

ROCE

19.0

Market Price of Marksans Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Marksans Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Feb 2025226.1
20 Feb 2025232.4
19 Feb 2025227.9
18 Feb 2025241.05
17 Feb 2025238.45
14 Feb 2025230.6
13 Feb 2025249.5
12 Feb 2025253.8
11 Feb 2025251.45
10 Feb 2025267.4

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

che

Weakness

1

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Marksans Pharma Ltd

Asset Value vs Market Value of Marksans Pharma Ltd

Market Value

10,246

Asset Value

Value addition

4.5 X

1,854

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Marksans Pharma Ltd10246
Sun Pharmaceuticals Industries Ltd394223
Divis Laboratories Ltd152610
Cipla Ltd119067
Torrent Pharmaceuticals Ltd102739
Dr Reddys Laboratories Ltd96124

Historical Market Cap of Marksans Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Marksans Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Marksans Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Marksans Pharma Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Marksans Pharma Ltd News Hub

Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules

Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketing Authoriz

Read more

21 Aug 24

Marksans Pharma gets EIR from USFDA for Goa facility

The inspection has been classified as voluntary action indicated (VAI) and has been closed according

Read more

20 Aug 24

Marksans Pharma's Verna unit successfully completes USFDA inspection

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its

Read more

20 Aug 24

Marksans Pharma to convene AGM

Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 Se

Read more

20 Aug 24

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Marksans Pharma Ltd

What is the EPS of Marksans Pharma Ltd stock?

The Earnings Per Share (EPS) of Marksans Pharma Ltd is 8.13. An EPS is the amount of net income attributed to each share of a common stock.

How is Marksans Pharma Ltd EPS calculated?

The EPS of Marksans Pharma Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Marksans Pharma Ltd report its EPS?

Marksans Pharma Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Marksans Pharma Ltd EPS?

Factors that influence the EPS of Marksans Pharma Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Marksans Pharma Ltd EPS growth indicate future performance?

Yes, consistent growth in Marksans Pharma Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions